Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

Open access
Osorio, Jorge E, Velez, Ivan D, Thomson, Cynthia, Lopez, Liliana, Jimenez, Alejandra, Haller, Aurelia A, Silengo, Shawn, Scott, Jaclyn, Boroughs, Karen L, Stovall, Janae L, Luy, Betty E, Arguello, John, Beatty, Mark E, Santangelo, Joseph, Gordon, Gilad S, Huang, Claire Y-H, Stinchcomb, Dan T·2014·The Lancet Infectious Diseases

Abstract

Summary Background Dengue virus is the most serious mosquito-borne viral threat to public health and no vaccines or antiviral therapies are approved for dengue fever. The tetravalent DENVax vaccine contains a molecularly characterised live attenuated dengue serotype-2 virus (DENVax-2) and three recombinant vaccine viruses expressing the prM and E structural genes for serotypes 1, 3, and 4 in the DENVax-2 genetic backbone. We aimed to assess the safety and immunogenicity of tetravalent DENVax formulations. Methods We undertook a randomised, double-blind, phase 1, dose-escalation trial between Oct 11, 2011, and Nov 9, 2011, in the Rionegro, Antioquia, Colombia. The first cohort of participants (aged 18–45 years) were randomly assigned centrally, via block randomisation, to receive a low-dose formulation of DENvax, or placebo, by either subcutaneous or intradermal administration. After a safety assessment, participants were randomly assigned to receive a high-dose DENVax formulation, or placebo, by subcutaneous or intradermal administration. Group assignment was not masked from study pharmacists, but allocation was concealed from participants, nurses, and investigators. Primary endpoints were frequency and severity of injection-site and systemic reactions within 28 days of each vaccination. Secondary endpoints were the immunogenicity of DENVax against all four dengue virus serotypes, and the viraemia due to each of the four vaccine components after immunisation. Analysis was by intention to treat for safety and per protocol for immunogenicity. Because of the small sample size, no detailed comparison of adverse event rates were warranted. The trial is registered with ClinicalTrials.gov, number NCT01224639. Findings We randomly assigned 96 patients to one of the four study groups: 40 participants (42%) received low-dose vaccine and eight participants (8%) received placebo in the low-dose groups; 39 participants (41%) received high-dose vaccine, with nine (9%) participants assigned to receive placebo. Both formulations were well tolerated with mostly mild and transient local or systemic reactions. No clinically meaningful differences were recorded in the overall incidence of local and systemic adverse events between patients in the vaccine and placebo groups; 68 (86%) of 79 participants in the vaccine groups had solicited systemic adverse events compared with 13 (76%) of 17 of those in the placebo groups. By contrast, 67 participants (85%) in the vaccine group had local solicited reactions compared with five (29%) participants in the placebo group. Immunisation with either high-dose or low-dose DENVax formulations induced neutralising antibody responses to all four dengue virus serotypes; 30 days after the second dose, 47 (62%) of 76 participants given vaccine seroconverted to all four serotypes and 73 (96%) participants seroconverted to three or more dengue viruses. Infectious DENVax viruses were detected in only ten (25%) of 40 participants in the low-dose group and 13 (33%) of 39 participants in the high-dose group. Interpretation Our findings emphasise the acceptable tolerability and immunogenicity of the tetravalent DENVax formulations in healthy, flavivirus-naive adults. Further clinical testing of DENVax in different age groups and in dengue-endemic areas is warranted. Funding Takeda Vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(14)70811-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 47

  1. Guzman, 2002, Dengue: an update, Lancet Infect Dis, 2, 33, 10.1016/S1473-3099(01)00171-2 · DOI · Paper page
  2. Wilder-Smith, 2008, Geographic expansion of dengue: the impact of international travel, Med Clin North Am, 92, 1377, 10.1016/j.mcna.2008.07.002 · DOI · Paper page
  3. Halstead, 2007, Dengue, Lancet, 370, 1644, 10.1016/S0140-6736(07)61687-0 · DOI · Paper page
  4. Halstead, 2005, Dengue virus: molecular basis of cell entry and pathogenesis, 25–27 June 2003, Vienna, Austria, Vaccine, 23, 849, 10.1016/j.vaccine.2004.03.069 · DOI
  5. Gibbons, 2007, Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences, Am J Trop Med Hyg, 77, 910, 10.4269/ajtmh.2007.77.910 · DOI · Paper page
  6. Halstead, 2013, Identifying protective dengue vaccines: guide to mastering an empirical process, Vaccine, 31, 4501, 10.1016/j.vaccine.2013.06.079 · doi:10.1016/j.vaccine.2013.06.079
  7. Butrapet, 2000, Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3, J Virol, 74, 3011, 10.1128/JVI.74.7.3011-3019.2000 · DOI · Paper page
  8. Osorio, 2011, Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever, Vaccine, 29, 7251, 10.1016/j.vaccine.2011.07.020 · doi:10.1016/j.vaccine.2011.07.020
  9. Huang, 2003, Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development, J Virol, 77, 11436, 10.1128/JVI.77.21.11436-11447.2003 · doi:10.1128/jvi.77.21.11436-11447.2003
  10. Osorio, 2011, Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques, Am J Trop Med Hyg, 84, 978, 10.4269/ajtmh.2011.10-0592 · DOI
  11. Brewoo, 2012, Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice, Vaccine, 30, 1513, 10.1016/j.vaccine.2011.11.072 · DOI
  12. Huang, 2013, Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax), PLoS Negl Trop Dis, 7, e2243, 10.1371/journal.pntd.0002243 · DOI
  13. Huang, 2010, The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion, Virology, 396, 305, 10.1016/j.virol.2009.10.027 · doi:10.1016/j.virol.2009.10.027
  14. Kitchener, 2006, Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults, Vaccine, 24, 1238, 10.1016/j.vaccine.2005.09.029 · doi:10.1016/j.vaccine.2005.09.029
  15. Durbin, 2006, The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers, Hum Vaccin, 2, 167, 10.4161/hv.2.4.2944 · doi:10.4161/hv.2.4.2944
  16. Nguyet, 2013, Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes, Proc Natl Acad Sci USA, 110, 9072, 10.1073/pnas.1303395110 · DOI · Paper page
  17. Brault, 2011, Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5′ untranslated region and amino acid substitutions in nonstructural proteins 1 and 3, Vector Borne Zoonotic Dis, 11, 683, 10.1089/vbz.2010.0150 · doi:10.1089/vbz.2010.0150
  18. Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 · DOI · Paper page
  19. Mahalingam, 2013, Call to action for dengue vaccine failure, Emerg Infect Dis, 19, 1335, 10.3201/eid1908.121864 · DOI
  20. Bhamarapravati, 1987, Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers, Bull World Health Organ, 65, 189
  21. Bhamarapravati, 1989, Study of bivalent dengue vaccine in volunteers, Lancet, 333, 1077, 10.1016/S0140-6736(89)92471-9 · doi:10.1016/s0140-6736(89)92471-9
  22. Vaughn, 1996, Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers, Vaccine, 14, 329, 10.1016/0264-410X(95)00167-Y · doi:10.1016/0264-410x(95)00167-y
  23. Kanesa-thasan, 2001, Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine, 19, 3179, 10.1016/S0264-410X(01)00020-2 · doi:10.1016/s0264-410x(01)00020-2
  24. Sabchareon, 2002, Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses, Am J Trop Med Hyg, 66, 264, 10.4269/ajtmh.2002.66.264 · doi:10.4269/ajtmh.2002.66.264
  25. Edelman, 2003, Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine, Am J Trop Med Hyg, 69, 48, 10.4269/ajtmh.2003.69.48 · DOI · Paper page
  26. Innis, 2003, Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command, Am J Trop Med Hyg, 69, 1, 10.4269/ajtmh.2003.69.6_suppl.0690001 · doi:10.4269/ajtmh.2003.69.6_suppl.0690001
  27. Sun, 2003, Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates, Am J Trop Med Hyg, 69, 24, 10.4269/ajtmh.2003.69.6_suppl.0690024 · DOI
  28. Simasathien, 2008, Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children, Am J Trop Med Hyg, 78, 426, 10.4269/ajtmh.2008.78.426 · doi:10.4269/ajtmh.2008.78.426
  29. Anderson, 2011, Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate, J Infect Dis, 204, 442, 10.1093/infdis/jir279 · DOI
  30. Watanaveeradej, 2011, Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants, Am J Trop Med Hyg, 85, 341, 10.4269/ajtmh.2011.10-0501 · doi:10.4269/ajtmh.2011.10-0501
  31. Thomas, 2013, A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults, Am J Trop Med Hyg, 88, 73, 10.4269/ajtmh.2012.12-0361 · doi:10.4269/ajtmh.2012.12-0361
  32. Durbin, 2010, Dengue vaccine candidates in development, Curr Top Microbiol Immunol, 338, 129
  33. Poo, 2011, Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity, Pediatr Infect Dis J, 30, e9, 10.1097/INF.0b013e3181fe05af · doi:10.1097/inf.0b013e3181fe05af
  34. Capeding, 2011, Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase 1 trial in the Philippines, Vaccine, 29, 3863, 10.1016/j.vaccine.2011.03.057 · doi:10.1016/j.vaccine.2011.03.057
  35. Durbin, 2011, Next-generation dengue vaccines: novel strategies currently under development, Viruses, 3, 1800, 10.3390/v3101800 · doi:10.3390/v3101800
  36. Lindow, 2012, Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans, PLoS Negl Trop Dis, 6, e1742, 10.1371/journal.pntd.0001742 · DOI
  37. Bentsi-Enchill, 2013, Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation, Vaccine, 31, 2603, 10.1016/j.vaccine.2013.03.038 · DOI
  38. Dayan, 2013, Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9–16 years in Brazil, Am J Trop Med Hyg, 89, 1058, 10.4269/ajtmh.13-0304 · doi:10.4269/ajtmh.13-0304
  39. Dayan, 2013, Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA, Vaccine, 31, 5047, 10.1016/j.vaccine.2013.08.088 · DOI
  40. Durbin, 2013, A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial, J Infect Dis, 207, 957, 10.1093/infdis/jis936 · doi:10.1093/infdis/jis936
  41. Lindow, 2013, Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles, Vaccine, 31, 3347, 10.1016/j.vaccine.2013.05.075 · DOI
  42. Villar, 2013, Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9–16 year olds: a randomized, controlled, phase II trial in Latin America, Pediatr Infect Dis J, 32, 1102, 10.1097/INF.0b013e31829b8022 · doi:10.1097/inf.0b013e31829b8022
  43. Beckett, 2011, Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial, Vaccine, 29, 960, 10.1016/j.vaccine.2010.11.050 · DOI · Paper page
  44. Bhamarapravati, 2000, Live attenuated tetravalent dengue vaccine, Vaccine, 18, 44, 10.1016/S0264-410X(00)00040-2 · doi:10.1016/s0264-410x(00)00040-2
  45. Sun, 2009, Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults, Hum Vaccin, 5, 33, 10.4161/hv.5.1.6348 · doi:10.4161/hv.5.1.6348
  46. Whitehead, 2007, Prospects for a dengue virus vaccine, Nat Rev Microbiol, 5, 518, 10.1038/nrmicro1690 · DOI · Paper page
  47. Wright, 2009, Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4Δ 30-4995 in healthy adult volunteers, Am J Trop Med Hyg, 81, 834, 10.4269/ajtmh.2009.09-0131 · DOI

Cited by

See all 158

Metadata

Authors
Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., Silengo, S., Scott, J., Boroughs, K. L., Stovall, J. L., Luy, B. E., Arguello, J., Beatty, M. E., Santangelo, J., Gordon, G. S., Huang, C. Y.-H., & Stinchcomb, D. T.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2014-09
Volume
14
Issue
9
Pages
830-838
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2119735531
Cited by
158
References
2
FWCI
20.22
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. https://app.cochat.ai/papers/10.1016/s1473-3099(14)70811-4
The paper
Osorio, J. E., Velez, I. D., Thomson, C., Lopez, L., Jimenez, A., Haller, A. A., Silengo, S., Scott, J., Boroughs, K. L., Stovall, J. L., Luy, B. E., Arguello, J., Beatty, M. E., Santangelo, J., Gordon, G. S., Huang, C. Y.-H., & Stinchcomb, D. T. (2014). Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(14)70811-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.